1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Boxer Capital, LLC Buys Intercept Pharmaceuticals Inc, BeiGene, uniQure NV, Sells The Medicines Co, Reata Pharmaceuticals Inc, Kiniksa Pharmaceuticals

Investment company Boxer Capital, LLC buys Intercept Pharmaceuticals Inc, BeiGene, uniQure NV, Global Blood Therapeutics Inc, DBV Technologies SA, Solid Biosciences Inc, Immunomedics Inc, Matinas BioPharma Holdings Inc, sells The Medicines Co, Reata Pharmaceuticals Inc, Kiniksa Pharmaceuticals, Rigel Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, Regulus Therapeutics Inc, Xenon Pharmaceuticals Inc, Bellerophon Therapeutics Inc, Syndax Pharmaceuticals Inc during the 3-months ended 2018Q4, according to the most recent filings of the investment company, Boxer Capital, LLC. As of 2018Q4, Boxer Capital, LLC owns 23 stocks with a total value of $805 million. These are the details of the buys and sells.

For the details of Boxer Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/boxer+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Boxer Capital, LLC
  1. BeiGene Ltd (BGNE) - 900,000 shares, 15.69% of the total portfolio. Shares added by 42.86%
  2. Solid Biosciences Inc (SLDB) - 3,498,272 shares, 11.65% of the total portfolio. Shares added by 21.40%
  3. PTC Therapeutics Inc (PTCT) - 2,155,000 shares, 9.19% of the total portfolio.
  4. WAVE Life Sciences Ltd (WVE) - 1,650,000 shares, 8.62% of the total portfolio. Shares added by 3.73%
  5. Mirati Therapeutics Inc (MRTX) - 1,565,560 shares, 8.25% of the total portfolio.
New Purchase: Intercept Pharmaceuticals Inc (ICPT)

Boxer Capital, LLC initiated holding in Intercept Pharmaceuticals Inc. The purchase prices were between $85.79 and $119.4, with an estimated average price of $103.17. The stock is now traded at around $106.68. The impact to a portfolio due to this purchase was 7.51%. The holding were 600,000 shares as of .

New Purchase: uniQure NV (QURE)

Boxer Capital, LLC initiated holding in uniQure NV. The purchase prices were between $22.8 and $33.5, with an estimated average price of $27.71. The stock is now traded at around $58.41. The impact to a portfolio due to this purchase was 4.3%. The holding were 1,200,000 shares as of .

New Purchase: Global Blood Therapeutics Inc (GBT)

Boxer Capital, LLC initiated holding in Global Blood Therapeutics Inc. The purchase prices were between $31.54 and $46.67, with an estimated average price of $37.55. The stock is now traded at around $52.00. The impact to a portfolio due to this purchase was 3.57%. The holding were 700,000 shares as of .

New Purchase: Immunomedics Inc (IMMU)

Boxer Capital, LLC initiated holding in Immunomedics Inc. The purchase prices were between $14.17 and $24.52, with an estimated average price of $19.73. The stock is now traded at around $18.57. The impact to a portfolio due to this purchase was 2.04%. The holding were 1,150,000 shares as of .

New Purchase: Matinas BioPharma Holdings Inc (MTNB)

Boxer Capital, LLC initiated holding in Matinas BioPharma Holdings Inc. The purchase prices were between $0.53 and $1.11, with an estimated average price of $0.78. The stock is now traded at around $1.13. The impact to a portfolio due to this purchase was 0.42%. The holding were 5,642,858 shares as of .

Added: BeiGene Ltd (BGNE)

Boxer Capital, LLC added to a holding in BeiGene Ltd by 42.86%. The purchase prices were between $107.01 and $170.68, with an estimated average price of $131.97. The stock is now traded at around $126.50. The impact to a portfolio due to this purchase was 4.71%. The holding were 900,000 shares as of .

Added: DBV Technologies SA (DBVT)

Boxer Capital, LLC added to a holding in DBV Technologies SA by 200.00%. The purchase prices were between $5.75 and $21.21, with an estimated average price of $15.82. The stock is now traded at around $7.44. The impact to a portfolio due to this purchase was 2.39%. The holding were 4,500,000 shares as of .

Added: Solid Biosciences Inc (SLDB)

Boxer Capital, LLC added to a holding in Solid Biosciences Inc by 21.40%. The purchase prices were between $21.32 and $42.57, with an estimated average price of $31.07. The stock is now traded at around $9.59. The impact to a portfolio due to this purchase was 2.05%. The holding were 3,498,272 shares as of .

Sold Out: Rigel Pharmaceuticals Inc (RIGL)

Boxer Capital, LLC sold out a holding in Rigel Pharmaceuticals Inc. The sale prices were between $2.08 and $3.36, with an estimated average price of $2.81.

Sold Out: Sunesis Pharmaceuticals Inc (SNSS)

Boxer Capital, LLC sold out a holding in Sunesis Pharmaceuticals Inc. The sale prices were between $0.24 and $2.21, with an estimated average price of $1.13.

Sold Out: Regulus Therapeutics Inc (RGLS)

Boxer Capital, LLC sold out a holding in Regulus Therapeutics Inc. The sale prices were between $0.84 and $2.52, with an estimated average price of $1.64.

Sold Out: Xenon Pharmaceuticals Inc (XENE)

Boxer Capital, LLC sold out a holding in Xenon Pharmaceuticals Inc. The sale prices were between $5.61 and $12.62, with an estimated average price of $8.8.

Sold Out: Bellerophon Therapeutics Inc (BLPH)

Boxer Capital, LLC sold out a holding in Bellerophon Therapeutics Inc. The sale prices were between $0.7 and $1.23, with an estimated average price of $0.96.

Sold Out: Syndax Pharmaceuticals Inc (SNDX)

Boxer Capital, LLC sold out a holding in Syndax Pharmaceuticals Inc. The sale prices were between $3.6 and $8.01, with an estimated average price of $5.39.

Reduced: The Medicines Co (MDCO)

Boxer Capital, LLC reduced to a holding in The Medicines Co by 83.43%. The sale prices were between $17.26 and $31.17, with an estimated average price of $23.01. The stock is now traded at around $27.86. The impact to a portfolio due to this sale was -3.88%. Boxer Capital, LLC still held 232,000 shares as of .

Reduced: Reata Pharmaceuticals Inc (RETA)

Boxer Capital, LLC reduced to a holding in Reata Pharmaceuticals Inc by 87.5%. The sale prices were between $48.76 and $76.44, with an estimated average price of $60.66. The stock is now traded at around $84.33. The impact to a portfolio due to this sale was -3.18%. Boxer Capital, LLC still held 50,000 shares as of .

Reduced: Kiniksa Pharmaceuticals Ltd (KNSA)

Boxer Capital, LLC reduced to a holding in Kiniksa Pharmaceuticals Ltd by 75.22%. The sale prices were between $16.25 and $28.09, with an estimated average price of $20.81. The stock is now traded at around $17.71. The impact to a portfolio due to this sale was -2.5%. Boxer Capital, LLC still held 290,577 shares as of .



Here is the complete portfolio of Boxer Capital, LLC. Also check out:

1. Boxer Capital, LLC's Undervalued Stocks
2. Boxer Capital, LLC's Top Growth Companies, and
3. Boxer Capital, LLC's High Yield stocks
4. Stocks that Boxer Capital, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK